Home » Archive by Category


San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

BioNano’s Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation

October 21, 2014 – 10:54 am | Edit Post

SAN DIEGO, Oct. 21, 2014 /PRNewswire/ – BioNano Genomics, the genome mapping company, announced today the latest genomics research centers to purchase an Irys™ System. Among them are the Salk Institute, the National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The French National Sequencing Center). Before Irys, obtaining a comprehensive view of a genome was a major hurdle, because next generation sequencing (NGS) does not deliver the scalability or reliability to detect and assemble large repetitive elements and structural variations. To achieve high quality genome analysis and comprehensive views of variation, a complete genome map is essential.

BioNano’s Irys System is a long-read genome mapping solution that reveals the location, order and orientation of clinically relevant genome components, including the length and location of long repeats and viral integration sites, which are often implicated in complex diseases such as cancer. Irys finds all types of structural variations in a single run, without prior knowledge of the variants.

The Salk Institute plans to implement the Irys System to develop more complete and accurate assemblies to better understand the contribution of structural variation for human and plant genomes. Structural variation comprises the majority of differences among individuals within any species. Next generation sequencing can quickly identify what pieces are in the puzzle, but an accurate map or picture is needed to fully assemble each individual genome.

Structural variation, which comprises a substantial portion of genome differences among individuals, has been connected to numerous diseases and is expected to be crucial to applying genomic information in personalized medicine and diagnostics. Structural variations include insertions, deletions, inversions, translocations and repeats. As a whole, they have sometimes been referred to as the “inaccessible genome,” because next generation sequencing (NGS) technologies in large part miss this vital information.

“The adoption by these four prestigious centers is telling of researchers’ response to the capabilities of BioNano’s Irys System as a ‘must-have’ technology,” said Todd Dickinson, Ph.D., vice president, Global Commercial Operations at BioNano Genomics. “BioNano’s Irys System streamlines the process of genome assembly, annotation, and structural variation analysis, and provides a single platform to perform large, comprehensive structural variation studies. Irys provides rapid and reliable access to this previously ‘inaccessible genome.’”

NCI will be using the Irys System to analyze the role of structural variation in the development and progression of cancer. At NISC, the Irys System will be available as a core technology to run human and non-human samples, including microbial, invertebrates and pathogens. Founded in 1996, Genoscope, which was involved in the sequencing of the human genome, has adopted the Irys System to detect structural variation and to complete genomes for various projects.

“Large-scale structural variation in particular has been implicated in a broad range of cancers and is essential to furthering our understanding of this disease,” said Dr. Dickinson. “Without technologies that can identify and organize all the structural variation within a cancer genome, the complexity of mutations and rearrangements cannot be untangled.”  

Dr. Dickinson concluded, “Enabling the cancer research community with the Irys system for translational research is a key part of our strategic mission and commercialization strategy. We are thrilled that the National Cancer Institute has adopted BioNano’s Irys System to provide a comprehensive picture of structural variation and enable a systematic understanding of the genetic drivers of cancer.”

About Irys

Irys makes it possible to routinely and accurately detect genomic structural variation and to finish genome assemblies. The fully automated Irys benchtop instrument uses the IrysChip to uncoil and confine long DNA molecules in proprietary Nanochannel Arrays™ where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging. Irys does not employ DNA fragmentation or amplification, which are typical with next-generation sequencing. The result is sequence information over extremely long “reads” ranging from hundreds of kilobases to a megabase, where the sample’s valuable structural information is preserved. Irys makes it possible for researchers to directly observe structural variants including replications, deletions, translocations and inversions.

About BioNano Genomics

Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. The Company’s platform provides researchers and clinicians the most comprehensive, organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by private investors and grant funding from genomics programs at federal agencies, including the NIH and NIST-ATP.


Notes: BioNano Genomics is a trademark of BioNano Genomics, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bionanos-irys-system-adopted-by-leading-genomics-centers-for-comprehensive-detection-of-human-genome-structural-variation-839245728.html
SOURCE BioNano Genomics

UCSF Medical Center Adopts Hi-Tech “Smart” Dressing for Chronic Wounds

October 21, 2014 – 8:02 am | Edit Post

SANTA CLARA, Calif., Oct. 21, 2014 /PRNewswire/ – OSNovative Systems, Inc., the maker of self-adaptive wound care dressings, announced today that its award-winning ENLUXTRATM “Any Wound” dressing has been adopted at the UCSF Medical Center for treating chronic wounds.

In the United States, the burden of managing chronic wounds is growing rapidly due to an aging population and the increased incidence of diabetes, obesity and associated co-morbidities:

About seven million patients suffer from chronic wounds
$25 billion is spent annually on chronic wound management
Over half of all foot ulcers become infected, requiring hospitalization; one in five require an amputation
Diabetic foot ulcers double the mortality risk
Infected wounds are dangerous and may result in sepsis and death in chronic wound patients Clinical effectiveness and affordability of the first “smart” wound care product featuring feedback-driven, polymeric dressing material take wound management to a radically new level.

Enluxtra represents a fundamentally new category of dynamic, multifunctional, self-adaptive wound care products. While in direct contact with the wound, the dressing material analyzes the wound condition; it then automatically and reversibly adjusts its function to accommodate the wound’s needs, which may frequently and unpredictably change.

Absorbed exudate and pathogens are locked inside the dressing, controlling infection and maceration; the dressing material releases moisture to dry areas of the wound, preventing desiccation. In effect, Enluxtra is suitable for any wound type at any healing stage.

“What’s impressive about this dressing is that you can use it from beginning to end on any wound,” said Dr. Alex Reyzelman, the Co-Director of UCSF Center for Limb Preservation. “Now we can carry one product and use it on almost everything.”

The super-absorptive dressing can be worn for up to 10 days, which results in both economic and clinical benefits. Reduced dressing change frequency brings significant cost savings to patients and healthcare providers, while fewer disruptions of wound homeostasis (a known critical condition for fast wound healing) aid uninterrupted healing process.

“One of the big challenges in wound care is keeping the wound at that “just right” level of moisture — not too wet and not too dry,” said Dr. Caroline Fife, the Medical Director of the Wound Clinic at St. Luke’s Hospital, The Woodlands, TX, and a prominent figure in the national wound care industry. “Enluxtra adapts to the changes in the amount of wound fluid, and patients love the way it feels. Enluxtra doesn’t stick to the wound, it is easy to apply and it is comfortable.”

The impact Enluxtra can make on the economics of wound management stems from three major factors: inventory reduction, simplified training (even patients themselves can use the product), and reduced treatment duration.

Economic factors aside, Enluxtra does more: it brings long-awaited relief to chronic wound sufferers, changing and saving people’s lives.­­­

“So far, out of all the things I’ve tried in all my years – and I’ve been treating wounds for 15 years – this is as close as it comes to a perfect dressing right now,” Dr. Reyzelman said. “I’m very excited about it because it’s actually doing what it’s designed to do.”

In almost two years on the market, Enluxtra has been used by more than 40,000 patients both at home and in leading healthcare organizations and hundreds of facilities nationwide, including major hospitals, long-term care and skilled nursing facilities, nursing homes, home health agencies, wound care and podiatry clinics.

About OSNovative SystemsOSNovative Systems, Inc. is a rapidly growing Silicon Valley start-up. The company develops, manufactures and sells proprietary devices for advanced wound management, combat/emergency medicine and cosmetic skin care. OSNovative Systems is headquartered in Santa Clara, Calif. For more information, visit www.AnyWound.com.

UC DisclaimerThe information stated above was prepared by OSNovative Systems and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of OSNovative Systems, or any of its products, by The Regents of the University of California, its officers, agents and employees.

Photo - http://photos.prnewswire.com/prnh/20141021/153390  
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ucsf-medical-center-adopts-hi-tech-smart-dressing-for-chronic-wounds-564657844.html
SOURCE OSNovative Systems, Inc.

Aurora Spine Announces Global Distribution Agreement for Sentio MMG(R) Nerve Mapping System

October 21, 2014 – 6:01 am | Edit Post

CARLSBAD, CALIFORNIA–(Marketwired – Oct. 21, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today that it has entered into a worldwide distribution and co-marketing agreement with Sentio, LLC to distribute the Sentio MMG® nerve mapping system.

MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company’s Lead Clinical Development Candidate

October 21, 2014 – 6:00 am | Edit Post

SAN DIEGO, Oct. 21, 2014 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company, announced today that it has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer.  The fully human antibody, recovered from patients undergoing cancer vaccine treatment at Memorial Sloan-Kettering Cancer Center, has entered GMP manufacturing to produce clinical trial supplies for a planned Phase 1 program to begin in the second half of 2015. The development plan calls for dual Phase 1 clinical trials to take place simultaneously.  One program will be aimed at demonstrating the utility of the radio-labeled antibody as a novel PET imaging agent for the diagnosis and management of pancreatic cancer.  The second program will determine the safety and potential utility of the full-length antibody as a treatment for the same cancer.

About HuMab 5B1

The HuMab 5B1 has demonstrated high specificity, affinity, and lack of cross-reactivity with similar antigens.  The antibody has also shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon, and small cell lung cancer.  Early toxicology results continue to produce an acceptable profile in acute and repeat dose toxicology models.  The antibody, when combined with a radio-label as a novel PET imaging agent, has demonstrated high image resolution of tumors in established animal models.  The company believes that the HuMab 5B1 antibody met all of the Company’s criteria for moving the product forward as a clinical development candidate.

About MabVax Antibody Discovery Technology

MabVax has developed an antibody discovery technology that surveys the protective immune response from many patients by examining blood samples to identify the ideal monoclonal antibody candidate against a specific target. We believe our approach to antibody discovery identifies antibody candidates with superior performance characteristics while minimizing many of the toxicity and drawbacks of other discovery technologies.  The company’s highly experienced researchers have utilized this technology to discover fully-human antibodies to a wide range of targets including antigens on cancer cells, bacteria, viruses, and toxins.  While the company’s technology is suitable to discover fully-human antibodies to highly infectious agents such as the Ebola virus, in response to recent inquiries, it does not have the specialized laboratory infrastructure to allow such an effort.

About MabVax

MabVax Therapeutics Holdings, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company’s proprietary vaccines. MabVax has the exclusive license to the therapeutic vaccines from Memorial Sloan-Kettering Cancer Center.  MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma ready for Phase II clinical development.

Additional information about the Company is available at www.mabvax.com.

Forward Looking Statements

This press release contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s development pipeline and stock symbol.  We have no assurance that all of the product development pipeline will be fully developed by the Company.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2013 and in the Proxy Statement dated July 25, 2014, as amended and supplemented from time to time and in our quarterly report on Form 10-Q for June 30, 2014.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-nominates-the-fully-human-antibody-humab-5b1-as-the-companys-lead-clinical-development-candidate-534292496.html
SOURCE MabVax Therapeutics Holdings, Inc.

Patheon(R) to Present Multiple Scientific Findings at 2014 AAPS Annual Meeting and Exposition

October 21, 2014 – 6:00 am | Edit Post

DURHAM, NC–(Marketwired – October 21, 2014) – Patheon, the pharmaceutical services business owned by DPx Holdings B.V., will showcase key capabilities and expertise with more than 20 scientists presenting posters on behalf of Patheon and Banner Life Sciences at this year’s AAPS Annual Meeting and Exposition from Sunday, Nov. 2 to Thursday, Nov. 6, in San Diego, Calif. The AAPS Annual Meeting and Exposition hosts top scientists from CROs and CMOs in the world each year to update industry leaders on advances in the field of pharmaceutical science.

Aptose Biosciences Announces Approval For Listing On The Capital Market Shares To Begin Trading Under The Symbol APTO

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO and TORONTO, Oct. 21, 2014 /PRNewswire/ – Aptose Biosciences Inc. (Aptose) (TSX:APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, announced today that its common shares…

Neurocrine Biosciences, Inc. Announces Initiation Of Phase 3 Study For VMAT2 Inhibitor NBI-98854

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a randomized, parallel-group, double…

Contract Research Organization Announces Clinical Trial Patient Rescue Program With A Pay-Per-Patient Enrolled Pricing Structure

October 21, 2014 – 5:00 am | Edit Post

COSTA MESA, Calif., Oct. 21, 2014 /PRNewswire-iReach/ — WCCT Global, a full service contract research organization headquartered in Southern California announced today the launch of a clinical trial patient recruitment…

Immunotech Laboratories Enters Into Agreement To Market Potential Ebola Virus Disease (???EVD???) Treatment And Implement Strategy For Company’s ITV-1 Infectious Diseases Treatment In Africa

October 21, 2014 – 5:00 am | Edit Post

MONROVIA, Calif.–(BUSINESS WIRE)–Immunotech Laboratories, Inc. (OTC PINK: IMMB) (Immunotech or the Company) and wholly-owned subsidiary Immunotech Laboratories, BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to…

Illumina, Inc. Reports Record Financial Results For Third Quarter Of Fiscal Year 2014

October 21, 2014 – 5:00 am | Edit Post

Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of $481 million, a 35% increase compared to $357 million in the third quarter of 2013 Help employers find you! Check out all the jobs and…